高级检索
当前位置: 首页 > 详情页

Sine oculis homeobox homolog 1 promotes DNA replication and cell proliferation in cervical cancer

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Huazhong Univ Sci & Technol,Tongji Med Coll,Tongji Hosp,Canc Biol Res Ctr,Wuhan 430074,Peoples R China [2]Southern Med Univ Guangzhou, Nanfang Hosp, Dept Obstet & Gynecol, Guangzhou, Guangdong, Peoples R China
出处:
ISSN:

关键词: Sine oculis homeobox homolog 1 DNA replication cell proliferation cervical cancer

摘要:
Malignant proliferation is the fundamental trait of tumor cells. The initiation of DNA replication represents a key process for cell proliferation, and has a marked impact on tumorigenesis and progression. Here we report that Sine oculis homeobox homolog 1 (SIX1) functions as a master regulator in DNA replication of cervical cancer cells. The expression of SIX1 was induced by the E7 oncoprotein of human papillomaviruses in cervical intraepithelial neoplasia and cervical cancer. The increase of SIX1 expression resulted in the upregulation of multiple genes related to the initiation of DNA replication, including the genes coding for the proteins in minichromosome maintenance complex (MCM2, MCM3, MCM6), DNA polymerase a-primase complex (POLA1, PRIM1, PRIM2), clamp loader (RFC3, RFC4, RFC5), DNA polymerase delta complex (POLD3) and DNA polymerase a complex (POLE2). In line with this, the increase of SIX1 expression enhanced DNA synthesis, accelerated G1 to S phase progression, and promoted the proliferation of cervical cancer cells and the growth of cervical cancer. Consistently, knockdown of SIX1 could hamper DNA synthesis, slow down G1 to S phase progression, and suppress tumor cell proliferation and tumor growth. Importantly, SIX1 could more efficiently promote anchorage-independent cell growth. These results suggest that the increase of SIX1 expression could promote tumorigenesis, progression and invasive growth of cervical cancer by promoting DNA replication, and that targeting SIX1 may have significant therapeutic value in cervical cancer treatment.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2013]版:
大类 | 3 区 医学
小类 | 4 区 肿瘤学
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学
JCR分区:
出版当年[2012]版:
Q2 ONCOLOGY
最新[2023]版:
Q1 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2012版] 出版当年五年平均 出版前一年[2011版] 出版后一年[2013版]

第一作者:
第一作者单位: [1]Huazhong Univ Sci & Technol,Tongji Med Coll,Tongji Hosp,Canc Biol Res Ctr,Wuhan 430074,Peoples R China
通讯作者:
通讯机构: [1]Huazhong Univ Sci & Technol,Tongji Med Coll,Tongji Hosp,Canc Biol Res Ctr,Wuhan 430074,Peoples R China [*1]Huazhong Univ Sci & Technol,Tongji Med Coll,Tongji Hosp,Canc Biol Res Ctr,1095 Jiefang Anv,Wuhan 430074,Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:434 今日访问量:0 总访问量:419 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)